Your browser doesn't support javascript.
loading
The Efficacy and Safety of Inetetamab and Pyrotinib in Combination with Vinorelbine for Second-line Therapy and Beyond in HER2-positive Metastatic Breast Cancer: A Single-institution Clinical Experience.
Wu, Fan; Chen, Mulan; Wang, Lili; Li, Nani; Wu, Xiufeng; Chen, Xinhua; Hong, Yi; Li, Chongyin; Lin, Lin; Chen, Kan; Huang, Weiwei; Liu, Jian.
Afiliação
  • Wu F; Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian Province, China
  • Chen M; Fujian Key Laboratory of Translational Cancer Medicine, Fuzhou, Fujian Province, China;
  • Wang L; Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian Province, China
  • Li N; Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian Province, China
  • Wu X; Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian Province, China
  • Chen X; Department of Breast Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian Province, China
  • Hong Y; Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian Province, China
  • Li C; Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian Province, China
  • Lin L; Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian Province, China
  • Chen K; Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian Province, China
  • Huang W; Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian Province, China
  • Liu J; Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian Province, China
Curr Cancer Drug Targets ; 2023 10 24.
Article em En | MEDLINE | ID: mdl-37916639
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Curr Cancer Drug Targets Assunto da revista: ANTINEOPLASICOS / NEOPLASIAS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Curr Cancer Drug Targets Assunto da revista: ANTINEOPLASICOS / NEOPLASIAS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China